There are a number of wound dressing products that VitroGro would not really replace. The product positioning of VitroGro is to accelerate wound healing while allowing the clinical team to still use their choice of dressing. Although, if VitroGro works really well healing wounds this means that the dressing product(s) are used for a shorter period of time.
I'm wanting to see them really ramp this up once they can sell, especially the UK and Germany, because they are only going to be accessing around 20% odd of the potential market and it will be years before they enter the US and not until at least Q4 2013 before they enter the other European countries.
- Forums
- ASX - By Stock
- TIS
- double blinded studies
double blinded studies, page-15
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TIS (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online